Response to conjugate pneumococcal and Haemophilus influenzae type b vaccines in asplenic patients

Vaccine

Volumn 29, Issue 4, 2011, Pages 675-680

  Meerveld Eggink, A ^a   de Weerdt, O ^a   van Velzen Blad, H ^a   Biesma, D H ^b   Rijkers, G T ^a  

^a ST ANTONIUS HOSPITAL   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Asplenia; Hib vaccination; Pneumococcal vaccination

Indexed keywords

ANTIBODY; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; PNEUMOCOCCUS VACCINE;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; ASPLENIA; FEMALE; HAEMOPHILUS INFECTION; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEROTYPE; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, BACTERIAL; BACTERIAL CAPSULES; FEMALE; HAEMOPHILUS VACCINES; HUMANS; IMMUNIZATION; IMMUNIZATION, SECONDARY; MALE; MIDDLE AGED; PNEUMOCOCCAL VACCINES;

EID: 78650569510     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.11.034     Document Type: Article

References (41)

1. Waghorn D.J. Overwhelming infection in asplenic patients: current best practice preventive measures are not being followed. J Clin Pathol 2001, 54(3):214-218.
2. Bisharat N., Omari H., Lavi I., Raz R. Risk of infection and death among post-splenectomy patients. J Infect 2001, 43(3):182-186.
3. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997, 46:1-24. (RR-8).
4. Shatz D.V. Vaccination considerations in the asplenic patient. Expert Rev Vaccines 2005, 4(1):27-34.
5. Guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen. Working Party of the British Committee for Standards in Haematology Clinical Haematology Task Force. BMJ 1996, 312(7028):430-434.
6. Davies J.M., Barnes R., Milligan D. British Committee for Standards in Haematology. Working Party of the Haematology/Oncology Task Force. Update of guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen. Clin Med 2002, 2(5):440-443.
7. Castagnola E., Fioredda F. Prevention of life-threatening infections due to encapsulated bacteria in children with hyposplenia or asplenia: a brief review of current recommendations for practical purposes. Eur J Haematol 2003, 71(5):319-326.
8. Update: pneumococcal polysaccharide vaccine usage-United States. Recommendations of the Immunization Practices Advisory Committee. Ann Intern Med 1984, 101(3):348-350.
9. Health Council of the Netherlands Pneumococcal vaccine in elderly adults and risk groups 2003, 2003 (10). Health Council of the Netherlands, The Hague.
10. Advisory Committee on Immunization Practices. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000, 49:1-35. (RR-9).
11. Hazlewood M., Kumararatne D.S. The spleen? Who needs it anyway?. Clin Exp Immunol 1992, 89(3):327-329.
12. Melles D.C., de Marie S. Prevention of infections in hyposplenic and asplenic patients: an update. Neth J Med 2004, 62(2):45-52.
13. Giebink G.S., Foker J.E., Kim Y., Schiffman G. Serum antibody and opsonic responses to vaccination with pneumococcal capsular polysaccharide in normal and splenectomized children. J Infect Dis 1980, 141(3):404-412.
14. van Dijk G.W., van Leeuwen H.J., van Gijn J., Hoepelman I.M. Missing spleen: indication for pneumococcal vaccination. Ned Tijdschr Geneeskd 2003, 147(10):425-428.
15. Overturf G.D. American Academy of Pediatrics. Committee on Infectious Diseases. Technical report: prevention of pneumococcal infections, including the use of pneumococcal conjugate and polysaccharide vaccines and antibiotic prophylaxis. Pediatrics 2000, 106(2 Pt 1):367-376.
16. Rose M.A., Schubert R., Strnad N., Zielen S. Priming of immunological memory by pneumococcal conjugate vaccine in children unresponsive to 23-valent polysaccharide pneumococcal vaccine. Clin Diagn Lab Immunol 2005, 12(10):1216-1222.
17. Bilukha O.O., Rosenstein N. National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2005, 54(RR-7):1-21.
18. Meerveld-Eggink A., de Weerdt O., Rijkers G.T., van Velzen-Blad H., Biesma D.H. Vaccination coverage and awareness of infectious risks in patients with an absent or dysfunctional spleen in the Netherlands. Vaccine 2008, 26(52):6975-6979.
19. Herrmann D.J., Hamilton R.G., Barington T., Frasch C.E., Arakere G., Makela O., et al. Quantitation of human IgG subclass antibodies to Haemophilus influenzae type b capsular polysaccharide. Results of an international collaborative study using enzyme immunoassay methodology. J Immunol Methods 1992, 148(1-2):101-114.
20. Kayhty H., Peltola H., Karanko V., Makela P.H. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1983, 147(6):1100.
21. Wernette C.M., Frasch C.E., Madore D., Carlone G., Goldblatt D., Plikaytis B., et al. Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin Diagn Lab Immunol 2003, 10(4):514-519.
22. Skovsted I.C., Kerrn M.B., Sonne-Hansen J., Sauer L.E., Nielsen A.K., Konradsen H.B., et al. Purification and structure characterization of the active component in the pneumococcal 22F polysaccharide capsule used for adsorption in pneumococcal enzyme-linked immunosorbent assays. Vaccine 2007, 25(35):6490-6500.
23. World Health Organization. Recommendations for the production and control of pneumococcal conjugate vaccines. WHO Technical Report Series, No. 927, Annex 2 2005.
24. Obaro S.K., Adegbola R.A., Chang I., Banya W.A., Jaffar S., Mcadam K.W., et al. Safety and immunogenicity of a nonavalent pneumococcal vaccine conjugated to CRM197 administered simultaneously but in a separate syringe with diphtheria, tetanus and pertussis vaccines in Gambian infants. Pediatr Infect Dis J 2000, 19(5):463-469.
25. Saaka M., Okoko B.J., Kohberger R.C., Jaffar S., Enwere G., Biney E.E., et al. Immunogenicity and serotype-specific efficacy of a 9-valent pneumococcal conjugate vaccine (PCV-9) determined during an efficacy trial in The Gambia. Vaccine 2008, 26(29-30):3719-3726.
26. Russell F.M., Balloch A., Tang M.L., Carapetis J.R., Licciardi P., Nelson J., et al. Immunogenicity following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine. Vaccine 2009, 27(41):5685-5691.
27. Balmer P., Cant A.J., Borrow R. Anti-pneumococcal antibody titre measurement: what useful information does it yield?. J Clin Pathol 2007, 60(4):345-350.
28. Bernatowska E., Kayhty H., Mikoluc B., Pac M., Berglof A. Difference response with antibodies to PPV and PCV in asplenic children. Abstracts of the 5th International Symposium on Pneumococci and Pneumococcal diseases. 2-6 April 2006 2006, Central Australia: Alice springs convention centre, Alice Springs.
29. Butler J.C., Breiman R.F., Campbell J.F., Lipman H.B., Broome C.V., Facklam R.R. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA 1993, 270(15):1826-1831.
30. Musher D.M., Ceasar H., Kojic E.M., Musher B.L., Gathe J.C., Romero-Steiner S., et al. Administration of protein-conjugate pneumococcal vaccine to patients who have invasive disease after splenectomy despite their having received 23-valent pneumococcal polysaccharide vaccine. J Infect Dis 2005, 191(7):1063-1067.
31. Smets F., Bourgois A., Vermylen C., Brichard B., Slacmuylders P., Leyman S., et al. Randomised revaccination with pneumococcal polysaccharide or conjugate vaccine in asplenic children previously vaccinated with polysaccharide vaccine. Vaccine 2007, 25(29):5278-5282.
32. Stoehr G.A., Rose M.A., Eber S.W., Heidemann K., Schubert R., Zielen S. Immunogenicity of sequential pneumococcal vaccination in subjects splenectomised for hereditary spherocytosis. Br J Haematol 2006, 132(6):788-790.
33. Stanford E., Print F., Falconer M., Lamden K., Ghebrehewet S., Phin N., et al. Immune response to pneumococcal conjugate vaccination in asplenic individuals. Hum Vaccine 2009, 5(2):85-91.
34. Mikoluc B., Kayhty H., Bernatowska E., Motkowski R. Immune response to the 7-valent pneumococcal conjugate vaccine in 30 asplenic children. Eur J Clin Microbiol Infect Dis 2008, 27(10):923-928.
35. de Roux A., Schmole-Thoma B., Siber G.R., Hackell J.G., Kuhnke A., Ahlers N., et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis 2008, 46(7):1015-1023.
36. Pollard A.J., Perrett K.P., Beverley P.C. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol 2009, 9(3):213-220.
37. O'Brien K.L., Hochman M., Goldblatt D. Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue?. Lancet Infect Dis 2007, 7(9):597-606.
38. Davidson M., Bulkow L.R., Grabman J., Parkinson A.J., Chamblee C., Williams W.W., et al. Immunogenicity of pneumococcal revaccination in patients with chronic disease. Arch Intern Med 1994, 154(19):2209-2214.
39. Torling J., Hedlund J., Konradsen H.B., Ortqvist A. Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia. Vaccine 2003, 22(1):96-103.
40. Jackson L.A., Benson P., Sneller V.P., Butler J.C., Thompson R.S., Chen R.T., et al. Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA 1999, 281(3):243-248.
41. Landgren O., Bjorkholm M., Konradsen H.B., Soderqvist M., Nilsson B., Gustavsson A., et al. A prospective study on antibody response to repeated vaccinations with pneumococcal capsular polysaccharide in splenectomized individuals with special reference to Hodgkin's lymphoma. J Intern Med 2004, 255(6):664-673.